Vivus, Inc. (VVUS) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) re-examined and...(read more
Shares of Vivus Inc (NASDAQ: VVUS) surged as much as 10% on Monday after the company disclosed in a regulatory filing that prescriptions for its flagship obesity drug Qsymia jumped 68% to 12,978 for...
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Vivus Inc. (VVUS) reported a loss of 40 cents per share in the third quarter of 2012, wider than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago loss of 10 cents...(read more